Huayiping® Voglibose Tablets
Specification: 0.1mg0.2mg0.3mg

National Medical Insurance Class B

Selected in national centralized procurement

Huayiping® Voglibose Tablets is an oral hypoglycemic drug and belongs to the representative product of α glycosidase inhibitors. This product inhibits the disaccharide hydrolase (α-glucosidase) that breaks down disaccharides into monosaccharides in the intestine, thereby delaying the digestion and absorption of sugars, thereby improving postprandial hyperglycemia. It is especially suitable for diabetic patients who rely on carbohydrates as their main source of energy and have high blood sugar after meals.


Primary Indications

Improves diabetic postprandial hyperglycemia


The Main Contraindication To Medication

1. Patients with severe ketosis, diabetic coma or pre-coma. (Because it is necessary to use infusion and insulin to quickly regulate high blood sugar, it is not suitable to take this product.) 

2. Patients with severe infection, patients before and after surgery, or patients with severe trauma. (Because it is necessary to regulate blood sugar by injecting insulin, it is not suitable to take this product.) 

3. Patients with a history of allergy to the ingredients of this product


Dosage Form

Tablets

Online Consultation
Huayiping® Voglibose Tablets
More Products